Literature DB >> 12438622

RNA interference directed against viral and cellular targets inhibits human immunodeficiency Virus Type 1 replication.

Rama M Surabhi1, Richard B Gaynor.   

Abstract

Human immunodeficiency virus type 1 (HIV-1) gene expression is regulated by both cellular transcription factors and Tat. The ability of Tat to stimulate transcriptional elongation is dependent on its binding to TAR RNA in conjunction with cyclin T1 and CDK9. A variety of other cellular factors that bind to the HIV-1 long terminal repeat, including NF-kappaB, SP1, LBP, and LEF, are also important in the control of HIV-1 gene expression. Although these factors have been demonstrated to regulate HIV-1 gene expression by both genetic and biochemical analysis, in most cases a direct in vivo demonstration of their role on HIV-1 replication has not been established. Recently, the efficacy of RNA interference in mammalian cells has been shown utilizing small interfering RNAs (siRNAs) to result in the specific degradation of host mRNAs and decreases the levels of their corresponding proteins. In this study, we addressed whether siRNAs directed against either HIV-1 tat or reverse transcriptase or the NF-kappaB p65 subunit could specifically decrease the levels of these proteins and thus alter HIV-1 replication. Our results demonstrate the specificity of siRNAs for decreasing the expression of these viral and cellular proteins and inhibiting HIV-1 replication. These studies suggest that RNA interference is useful in exploring the biological role of cellular and viral regulatory factors involved in the control of HIV-1 gene expression.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12438622      PMCID: PMC136685          DOI: 10.1128/jvi.76.24.12963-12973.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  91 in total

Review 1.  NF-kappaB at the crossroads of life and death.

Authors:  Michael Karin; Anning Lin
Journal:  Nat Immunol       Date:  2002-03       Impact factor: 25.606

2.  Tat is required for efficient HIV-1 reverse transcription.

Authors:  D Harrich; C Ulich; L F García-Martínez; R B Gaynor
Journal:  EMBO J       Date:  1997-03-17       Impact factor: 11.598

3.  NF-kappa B: ten years after.

Authors:  P A Baeuerle; D Baltimore
Journal:  Cell       Date:  1996-10-04       Impact factor: 41.582

4.  Purification of a Tat-associated kinase reveals a TFIIH complex that modulates HIV-1 transcription.

Authors:  L F García-Martínez; G Mavankal; J M Neveu; W S Lane; D Ivanov; R B Gaynor
Journal:  EMBO J       Date:  1997-05-15       Impact factor: 11.598

5.  The kappaB sites in the human immunodeficiency virus type 1 long terminal repeat enhance virus replication yet are not absolutely required for viral growth.

Authors:  B K Chen; M B Feinberg; D Baltimore
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

6.  Enhanced processivity of RNA polymerase II triggered by Tat-induced phosphorylation of its carboxy-terminal domain.

Authors:  C A Parada; R G Roeder
Journal:  Nature       Date:  1996-11-28       Impact factor: 49.962

7.  A system for stable expression of short interfering RNAs in mammalian cells.

Authors:  Thijn R Brummelkamp; René Bernards; Reuven Agami
Journal:  Science       Date:  2002-03-21       Impact factor: 47.728

8.  Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells.

Authors:  Nan Sook Lee; Taikoh Dohjima; Gerhard Bauer; Haitang Li; Ming-Jie Li; Ali Ehsani; Paul Salvaterra; John Rossi
Journal:  Nat Biotechnol       Date:  2002-05       Impact factor: 54.908

Review 9.  Potential new therapies for the treatment of HIV-1 infection.

Authors:  Jon H Condra; Michael D Miller; Daria J Hazuda; Emilio A Emini
Journal:  Annu Rev Med       Date:  2002       Impact factor: 13.739

10.  NF-kappa B RelA-deficient lymphocytes: normal development of T cells and B cells, impaired production of IgA and IgG1 and reduced proliferative responses.

Authors:  T S Doi; T Takahashi; O Taguchi; T Azuma; Y Obata
Journal:  J Exp Med       Date:  1997-03-03       Impact factor: 14.307

View more
  65 in total

Review 1.  Nucleic acid-based immune system: the antiviral potential of mammalian RNA silencing.

Authors:  Leonid Gitlin; Raul Andino
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

Review 2.  RNA interference: antiviral weapon and beyond.

Authors:  Quan-Chu Wang; Qing-He Nie; Zhi-Hua Feng
Journal:  World J Gastroenterol       Date:  2003-08       Impact factor: 5.742

3.  Lentiviral delivery of short hairpin RNAs protects CD4 T cells from multiple clades and primary isolates of HIV.

Authors:  Sang-Kyung Lee; Derek M Dykxhoorn; Priti Kumar; Shahin Ranjbar; Erwei Song; Laura E Maliszewski; Vanessa François-Bongarçon; Anne Goldfeld; N Manjunath Swamy; Judy Lieberman; Premlata Shankar
Journal:  Blood       Date:  2005-04-14       Impact factor: 22.113

Review 4.  RNAi therapeutics: principles, prospects and challenges.

Authors:  Lars Aagaard; John J Rossi
Journal:  Adv Drug Deliv Rev       Date:  2007-03-16       Impact factor: 15.470

Review 5.  RNA interference and antiviral therapy.

Authors:  Yan Ma; Chu-Yan Chan; Ming-Liang He
Journal:  World J Gastroenterol       Date:  2007-10-21       Impact factor: 5.742

Review 6.  Optimizing siRNA delivery to the genital mucosa.

Authors:  Joseph A Katakowski; Deborah Palliser
Journal:  Discov Med       Date:  2011-02       Impact factor: 2.970

7.  RNA interference-mediated virus clearance from cells both acutely and chronically infected with the prototypic arenavirus lymphocytic choriomeningitis virus.

Authors:  Ana B Sánchez; Mar Perez; Tatjana Cornu; Juan Carlos de la Torre
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

8.  Inflammation induces lymphangiogenesis through up-regulation of VEGFR-3 mediated by NF-kappaB and Prox1.

Authors:  Michael J Flister; Andrew Wilber; Kelly L Hall; Caname Iwata; Kohei Miyazono; Riccardo E Nisato; Michael S Pepper; David C Zawieja; Sophia Ran
Journal:  Blood       Date:  2009-11-09       Impact factor: 22.113

Review 9.  RNA interference-based therapeutics for human immunodeficiency virus HIV-1 treatment: synthetic siRNA or vector-based shRNA?

Authors:  Sandesh Subramanya; Sang-Soo Kim; N Manjunath; Premlata Shankar
Journal:  Expert Opin Biol Ther       Date:  2010-02       Impact factor: 4.388

10.  Human immunodeficiency virus type 1 escape from RNA interference.

Authors:  Daniel Boden; Oliver Pusch; Frederick Lee; Lynne Tucker; Bharat Ramratnam
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.